IR Press releases 2023-05-17

Gradientech: Interim report 1 January – 31 March 2023

Gradientech AB (publ) interim report for Q1 2023 is now available on the company's website

First quarter January-March 2023

  • Net sales amounted to KSEK 380 (0).
  • Profit after tax amounted to KSEK -18,063 (-15,171).
  • Earnings per share before and after dilution were SEK -1.08 (-1.04).
  • Cash flow from operating activities amounted to KSEK -18,068 (-14,982).
  • Cash and cash equivalents on the balance sheet date amounted to KSEK 25,993 (74,020).
  • Equity as of March 31, 2023 amounted to KSEK 40,731 (78,598).
  • On January 18, 2023, the subscription period for the rights issue ended, which started on December 27, 2022. The final outcome comprised a total of 1,271,057 subscribed shares, which provided Gradientech with approximately SEK 26.1 million before deduction of issue costs. As a result of the Rights Issue, the share capital increased by SEK 127,105.70 to a total of SEK 1,724,525.00 and the number of shares increased by 1,271,057 to a total of 17,245,250 shares.

Significant events after the end of the period

  • Within the framework of the authorization granted by the Annual General Meeting, the Board of Directors resolved on 4 April 2023 to carry out a directed issue to the commercial partner a.d.a SRL of 550,000 shares at a price of SEK 20.50 per share. As a result of the directed issue, the share capital increased by SEK 55,000 to a total of SEK 1,779,525.00 and the number of shares increased to a total of 17,795,250 shares. The issue was registered with the Swedish Companies Registration Office on April 25, 2023.
  • In April, Gradientech exhibited at ECCMID in Copenhagen, the world’s leading congress for both industry and clinic in clinical microbiology and infectious diseases. At the congress, Gradientech presented data confirming that QuickMIC® provides accurate results in 2-4 hours.

For more information please contact:
Sara Thorslund, PhD, CEO Gradientech
Tel: +46 736 29 35 80

Urban Adolfsson, CFO

Ann Charlotte Svensson, Investor Relations